Bumetanide - Only For Children Pharmaceuticals/Swedish Orphan Biovitrum

Drug Profile

Bumetanide - Only For Children Pharmaceuticals/Swedish Orphan Biovitrum

Alternative Names: Bumetanide - Only For Children Pharmaceuticals/Swedish Orphan Biovitrum (Sobi)

Latest Information Update: 17 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Only for Children Pharmaceuticals
  • Class Antihypertensives; Benzoic acids; Heart failure therapies; Sulfonamides
  • Mechanism of Action Ion pump modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Neonatal seizures

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 30 Aug 2011 Phase-I/II clinical trials in Neonatal seizures in Finland (IV)
  • 30 Aug 2011 Phase-I/II clinical trials in Neonatal seizures in Ireland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top